In metastatic disease, Hamid et al. [79] have reported the improved outcome of ipilimumab therapy among patients with elevated tumor infiltrating lymphocyte counts (TIL) and elevated Treg and IDO levels at pretreatment biopsy. Here, IDO1 is linked to neoplasm.